[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-overdose\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-overdose":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,97,122,146,173,193,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100609784","behavioral-safety-and-fentanyl-education-bsafe-100609784",false,"NCT07219082","Behavioral Safety and Fentanyl Education: BSAFE","BSAFE","Inclusion Criteria:\n\n1. Aged 18 years or older,\n2. Reports intentional cocaine or methamphetamine use ≥7 of past 30 days,\n3. Urine positive for cocaine or methamphetamine and negative for opioids\u002Ffentanyl prior to enrollment\n4. Be able to provide the names of at least 2 persons who can consistently locate their whereabouts.\n5. Reports at least one suspected unintentional fentanyl use event, including unexpected sedation or unexpected fentanyl-positive bodily fluid drug testing result.\n\nExclusion Criteria:\n\n1. Reports past 30-day intentional use of any opioid or ongoing use of an opioid antagonist (e.g., naltrexone)\n2. Intends to leave area in coming year,\n3. Unable to communicate in English or Spanish,\n4. Any other condition that, in the PI's judgment, interferes with safe study participation or adherence to study procedures.",true,"ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","BSAFE is a randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among people who use stimulants who may have unintentional fentanyl use (UFU). It includes an established overdose education curriculum within an Informational-Motivation-Behavior (IMB) model. This study will test the efficacy of BSAFE vs attention-control.",[27,28],"Drug Overdose","Drug Overdose Accidental","RECRUITING","2026-08-14",{"date":32,"type":33},"2026-08-18","ACTUAL",{"date":35,"type":33},"2026-08-11",{"date":37,"type":21},"2030-01-15",{"name":39,"class":40},"San Francisco Department of Public Health","OTHER_GOV",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":62,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100648636","clinician-practice-companion-to-address-youth-substance-use-100648636","NCT07725289","Clinician Practice Companion to Address Youth Substance Use","Inclusion Criteria:\n\n* Ages 14 to 24 years.\n* Uses drugs or alcohol (past year).\n* Receiving care at a participating study site.\n\nExclusion Criteria:\n\n* Cognitive limitations or intellectual disabilities that prevent provision of informed consent.\n* Any medical or psychiatric condition causing acute distress or requiring emergency evaluation.\n* Current membership on a study Community Advisory Board.","14 Years","24 Years",{"count":51,"type":21},60,[24],"Substance use, including the use of opioids, cannabis, and other drugs, is common among adolescents and young adults, and overdose has become a leading cause of death among youth in Canada and the United States. Many young people who use substances also experience co-occurring mental health concerns. Evidence-based approaches to youth substance use care exist, including harm reduction, overdose prevention (such as naloxone and take-home drug testing strips), and medications for addiction treatment. These approaches remain adult-oriented, however, unevenly implemented in youth-serving settings, and insufficiently centered on the needs and goals of youth and their families.\n\nThis study develops and pilot tests a written \"practice companion\" that helps clinicians and other trusted adults provide developmentally appropriate substance use care to youth ages 14 to 24 in hospital and community settings. The practice companion offers practical, easy-to-use guidance organized by substance and by pattern of use. It addresses cannabis and other substances that youth commonly use and that clinicians frequently seek support with, alongside a strong focus on overdose prevention through its core elements: naloxone, take-home drug testing strips, harm reduction education, and medications for opioid use disorder. It also attends to co-occurring mental health needs and to how gender, sexuality, housing instability, and other social and structural contexts shape substance use and care.\n\nThe research team will first interview youth who use substances, their families and caregivers, and clinicians to learn how each element of care should be adapted for young people. The team will then produce the practice companion and pilot test it with 60 youth across three sites, in British Columbia, Québec, and Massachusetts. After receiving care guided by the practice companion, youth will complete an interview about whether the care was relevant, useful, appropriate, and acceptable. Families and clinicians will also be interviewed to assess how feasible, sustainable, and faithful to its design the practice companion is in practice.\n\nThroughout the study, the team will work closely with youth and families who have lived experience through a community-based participatory research approach that includes Community Advisory Boards. The work centers equity for Black, Indigenous, and other racialized youth, Two-Spirit and LGBTQ+ youth, and youth experiencing housing instability. Findings will guide a larger future study of the practice companion's effectiveness.",[55,56,57,58,59,27,60,61],"Substance Use","Substance-Related Disorders","Adolescent Substance Use","Cannabis Use","Opioid Use Disorder","Overdose Prevention","Co-occurring Mental Health Conditions",[63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84],"Adolescents","Young adults","Youth","Substance use","Substance use care","Cannabis","Naloxone","Harm reduction","Take-home drug testing strips","Fentanyl","Medications for opioid use disorder (MOUD)","Buprenorphine","Methadone","Overdose prevention","Co-occurring mental health","Youth- and family-centred care","Patient-reported outcomes","Health equity","Implementation science","ADAPT-ITT","Community-based participatory research","Toolkit","NOT_YET_RECRUITING","2026-07-23",{"date":88,"type":33},"2026-07-27",{"date":90,"type":21},"2027-01",{"date":92,"type":21},"2029-12",{"name":94,"class":95},"Massachusetts General Hospital","OTHER",5,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100642004","the-enhance-project-toolkit-100642004","NCT07649278","The ENHANCE Project Toolkit","Mobile Health Strategies to Support Longitudinal Engagement in Comprehensive, Community-based Prevention Services for People Who Use Drugs (Aim 3)","Inclusion Criteria (Pilot Participant):\n\n* Be at least 18 years old\n* Be able to read and write in English\n* Report drug use in the past 30 days, defined as\n\n  * Any use of illicit stimulants, opioids, OR\n  * Use of prescription opioids by a route other than \"by mouth\u002Fswallowed\"\n* Additionally report recent drug use of at least twice in the past 7 days\n* Have NOT used any of the following harm reduction services in the past 6 months:\n\n  * In-person community-based prevention services for people who use drugs\n  * Overdose crisis hotlines\n  * Online mail-order prevention supply delivery\n  * Apps for supporting addiction treatment or recovery\n\nInclusion Criteria (Peer Mentor Participant):\n\n* Be at least 18 years old\n* Be able to read and write in English\n* Have served as a member of the existing Community Leadership Team.\n\nExclusion Criteria:\n\n* Are under the age of 18\n* Have impaired decision making capacity at the time of screening\n* Do not have the ability to participate in screening and enrollment activities in any one of the following ways:\n\n  * Traveling to their nearest participating Vivent Health health center\n  * Coordinating a visit with the Vivent Health harm reduction mobile unit\n  * Accessing and completing the online screening survey on a personal wifi\u002Finternet enabled device",{"count":105,"type":21},40,[24],"This study will examine the feasibility, appropriateness, and acceptability of a bundle of smartphone-based tools for lowering overdose risk. 40 participants will be enrolled and can expect to be on study for up to 9 months.",[109,27,110],"Substance Related Disorder","eHealth",[112,59],"Substance Use Disorder","2026-07-10",{"date":115,"type":33},"2026-07-14",{"date":117,"type":33},"2026-07-01",{"date":119,"type":21},"2027-06",{"name":121,"class":95},"University of Wisconsin, Madison",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":41},"100463910","a-setting-focus-overdose-prevention-intervention-100463910","NCT05320835","A Setting Focus Overdose Prevention Intervention","A Geospatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs in Baltimore, Maryland","Oasis","Inclusion Criteria:\n\n* Current drug user (opioid use in the prior two weeks)\n\nExclusion Criteria:\n\n* Any mental or physical health impairment that impedes ability to participate",{"count":131,"type":21},285,[24],"A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).",[135,136,27],"HIV Infections","HCV","2026-05-19",{"date":139,"type":33},"2026-05-22",{"date":141,"type":33},"2022-04-30",{"date":143,"type":21},"2027-05-30",{"name":145,"class":95},"Johns Hopkins Bloomberg School of Public Health",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":41},"100633604","justice-community-overdose-innovation-network-ii-tcu-hub-100633604","NCT07528846","Justice Community Overdose Innovation Network II TCU Hub","Justice Community Overdose Innovation Network II TCU Hub: TCU Building Resilient Initiatives for Deflection Through Greater Engagement Project (TCU BRIDGE to Deflection Project)","JCOIN II TCU","Staff\n\nInclusion Criteria:\n\n* Directly involved in Deflection services, including:\n* Making referrals (e.g., law enforcement, first responders, community agencies) \\& Providing services to participants (e.g., case managers, peer specialists, coordinators);\n* Aged 18 years or older;\n* Able to complete surveys in English;\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Not affiliated with a participating Deflection agency;\n* No role in Deflection referral or service delivery;\n* Under age 18;\n* Unable or unwilling to provide informed consent\n\nClients\n\nInclusion Criteria:\n\n* Aged 18 years or older;\n* Enrolled in a Deflection program within a participating community;\n* Between 1 and 12 months post-enrollment at time of recruitment;\n* Documented history of substance use disorder (SUD) or risk for SUD;\n* Priority for individuals reporting opioid and\u002For stimulant use within the past year;\n* Able to complete survey and\u002For interview; Willing to provide informed consent\n\nExclusion Criteria:\n\n* Under age 18;\n* Not enrolled in a Deflection program;\n* Insufficient exposure to Deflection (\\\u003C1 month);\n* Unable or unwilling to provide informed consent\n\nCitizens\n\nInclusion Criteria:\n\n* Aged 18 years or older;\n* Resident of a participating community;\n* Represents general community population (including individuals with or without lived experience of SUD\u002FCLS involvement);\n* Able to participate in: Surveys and\u002For Community Listening Sessions;\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Under age 18;\n* Not residing in a participating community;\n* Unable or unwilling to provide informed consent\n\nWorkgroup\n\nInclusion Criteria:\n\n* Aged 18 years or older;\n* Identified as a community or agency leader\u002Fstakeholder involved in Deflection programming;\n* Member of a DAG within a participating community;\n* Represents one of the required stakeholder roles: Law enforcement leadership or staff, Behavioral health leadership or staff Health professional, Community representative (citizen);\n* Able to participate in meetings, surveys, and\u002For focus groups;\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Not part of a DAG in a participating community;\n* Does not hold a role relevant to Deflection leadership or decision-making;\n* Under age 18;\n* Unable or unwilling to provide informed consent",{"count":155,"type":21},1620,[24],"The current study proposes to use a Hybrid Type 3 implementation research strategy to: 1) Significantly enhance our understanding of public health outcomes \\[e.g., overdose incidents and substance-use (SU)-related Emergency Medical Service (EMS) contacts\\] and public safety outcomes (e.g., drug-related arrests) associated with Deflection and Pre-Arrest Diversion initiatives (DPAD, hereafter referred to as Deflection); and 2) Create a lasting contribution to the fields of research focused on SU and the criminal legal system (CLS) by advancing knowledge of effective implementation strategies involving the critical role of community engagement in Deflection. The highly experienced team of Multiple PIs, senior-level collaborators from both Deflection and Community Behavioral Health (CBH), state-level evaluation partners, a national stakeholder advisory group, and CLS and behavioral health partners within each community have teamed up to carry out the proposed project. The study approach uses a hybrid implementation-effectiveness design to examine strategies to improve opioid and stimulant relevant outcomes, and specifically proposes to test the implementation-effectiveness of 2 strategy bundles to promote Deflection models through a CORE community engagement bundle (designed to facilitate community stakeholder engagement) and ENHANCED community engagement bundle (CORE plus a component to systematically involve community advocates) on improving implementation as well as public safety and health outcomes. The proposed randomized control trial includes a total of 20 geographically distinct clinical research performance sites (i.e., 20 communities spanning 5 states; New Mexico, Illinois, Wisconsin, Colorado, and Pennsylvania), with 3-5 communities per state and the inclusion of key CLS and CBH stakeholders within each site. The large scope of the project will maximize potential generalizability of study results and sustainability of implementation strategies.",[159,27,160],"Substance Use Disorder (SUD)","Criminal Behavior",[162,163],"deflection","pre-arrest diversion","2026-04-07",{"date":166,"type":33},"2026-04-14",{"date":168,"type":21},"2026-07",{"date":170,"type":21},"2029-05",{"name":172,"class":95},"Texas Christian University",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":41},"100541223","social-network-overdose-prevention-and-education-intervention-100541223","NCT06327061","Social Network Overdose Prevention and Education Intervention","A Social Diffusion Fatal Overdose Prevention Intervention: Assessing the Effectiveness of People Who Use Opioids as Peer Educators in Training Using & Non-using Networks on Overdose & Stigma Reduction","Inclusion Criteria:\n\n* self-reported illicit opioid use at least 2 times in the past two weeks;\n* age 18 and older;\n* living in the Baltimore metropolitan region;\n* willing to engage in peer education; and\n* having and willing to recruit at least one non-using network member.\n\nExclusion Criteria:\n\nParticipants without the cognitive ability to provide informed consent and have the physical ability to participate in in-person intervention sessions.",{"count":181,"type":21},600,[24],"The purpose of this study is to test a social intervention focused on overdose prevention and care. In the investigators prior work, the investigators have shown that people who use opioids (PWUO) can be effective peer educators (PEs).",[27],"2026-03-02",{"date":187,"type":33},"2026-03-04",{"date":189,"type":33},"2024-06-01",{"date":191,"type":21},"2029-04-01",{"name":145,"class":95},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":201,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":41},"100607785","clinical-and-biological-signs-of-dapagliflozin-overdose-in-icu-patients-with-metformin-poisoning-100607785","NCT07193069","Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Admission to an intensive care unit (ICU) due to acute drug poisoning\n* Documented exposure to either:\n* Metformin alone\n* Metformin in combination with dapagliflozin\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* No exposure to metformin\n* Exposure to dapagliflozin without metformin",{"count":200,"type":21},50,"OBSERVATIONAL","This study looks at patients admitted to intensive care for drug poisoning involving metformin, a common diabetes medication. Researchers will compare two groups: patients who overdosed on metformin alone and those who took both metformin and dapagliflozin, another diabetes drug. The goal is to find clinical or laboratory signs that could help doctors quickly recognize a dapagliflozin overdose in this context, which could improve treatment and patient outcomes.",[27,204,205,206,207,208],"Metformin","Dapagliflozin","Lactic Acidosis","Diabetic Ketoacidosis","Intensive Care Units","2025-09-24",{"date":211,"type":33},"2025-09-25",{"date":213,"type":33},"2025-04-11",{"date":215,"type":21},"2026-04-11",{"name":217,"class":95},"Centre Hospitalier de Saint-Denis",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":226,"targetDuration":228,"studyType":201,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":258},"100450503","cytosorb-treatment-of-critically-ill-patients-registry-100450503","NCT05146336","CytOSorb TreatMent Of Critically Ill PatientS Registry","CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting","COSMOS","Inclusion Criteria:\n\n1. Planned OR actual CytoSorb® 300 mL device utilization\n2. Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n1. Use of the CytoSorb® 300 mL device for antithrombotic removal only\n2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only\n3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.",{"count":227,"type":21},3000,"3 Months","Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care",[231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,27,247],"Septic Shock","Acute Respiratory Distress Syndrome","Trauma","Rhabdomyolysis","Cardiogenic Shock","Pancreatitis","Acute on Chronic Liver Failure","Acute Liver Failure","Burns","Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)","Extracorporeal Life Support","Postoperative Endocarditis","Hemophagocytic Lymphohistiocytoses","Liver Transplant; Complications","Infectious Disease","Postoperative Vasoplegic Syndrome","Sepsis","2025-09-10",{"date":250,"type":33},"2025-09-11",{"date":252,"type":33},"2022-06-22",{"date":254,"type":21},"2032-09",{"name":256,"class":257},"CytoSorbents, Inc","INDUSTRY",28]